Aquestive Q4 Revenue $13.02M, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Should l Buy AQST?
Reports Q4 revenue $13.02M, consensus $13.28M. "We are well-positioned in 2026 to advance Anaphylm, the first and only oral epinephrine rescue medication, towards approval for patients around the world," said Daniel Barber, President and Chief Executive Officer of Aquestive. "We continue to believe the value proposition will be transformative and ultimately save lives. We are focused on rapidly addressing the human factors focused deficiencies cited by the FDA in their recent Complete Response Letter. Our commercial infrastructure is intact and transferable to our new timeline, the allergy market continues to grow, and patient preference remains strongly in favor of the innovation Anaphylm represents. As recently announced, we have strengthened our leadership with the addition of Dr. Greenhawt, an internationally recognized expert in allergy and immunology, as the Chief Medical Officer of the Company. Additionally, we remain well-positioned financially to launch Anaphylm in the U.S., if approved by the FDA. We've never been more confident in Anaphylm's potential to make a meaningful difference for the allergy community."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AQST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AQST
Wall Street analysts forecast AQST stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.140
Low
6.00
Averages
9.00
High
12.00
Current: 4.140
Low
6.00
Averages
9.00
High
12.00
About AQST
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Class Action Lawsuit for Aquestive Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, allowing investors to pursue compensation without financial burden.
- Case Background: The lawsuit alleges that the defendants failed to disclose critical human factors related to the use of Aquestive's New Drug Application (NDA) for its sublingual film, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's transparency and compliance.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
Faruqi & Faruqi Encourages Investors to Contact Regarding Aquestive Losses
- Legal Investigation: Faruq & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. for securities purchased between June 16, 2025, and January 8, 2026, highlighting concerns for investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss legal options, demonstrating a commitment to client service.
- Class Action Deadline: Investors should note that May 4, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action against the company, making this date critical for potential claimants.
- Company Background: Aquestive Therapeutics, Inc. (NASDAQ:AQST) focuses on drug delivery technologies and is currently facing legal challenges that may impact investor confidence and market performance.
See More
Rosen Law Firm Alerts Investors of Class Action for Aquestive Therapeutics
- Class Action Notification: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ:AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which mitigates financial risk for investors and encourages broader participation.
- Case Background: The lawsuit alleges that the defendants failed to disclose the true state of Aquestive's New Drug Application (NDA), particularly concealing human factors related to the use of its sublingual film, resulting in investor losses when the truth emerged, highlighting significant governance and transparency issues within the company.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and influence in this field.
See More
Reminder of Class Action for Aquestive Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, to apply as lead plaintiffs by May 4, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, allowing them to seek legal recourse without financial burden.
- Case Background: The lawsuit alleges that the defendants made false or misleading statements regarding the New Drug Application (NDA) process, failing to disclose critical human factors involved in the use of their sublingual film, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first by ISS Securities Class Action Services in 2017, highlighting its expertise and success in this field.
See More
Faruqi & Faruqi Investigates Securities Fraud Claims Against Aquestive
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Aquestive Therapeutics, Inc. for actions between June 16, 2025, and January 8, 2026, urging investors to seek lead plaintiff status in a class action by the May 4, 2026 deadline.
- Stock Price Plunge: On January 9, 2026, Aquestive's stock fell by $2.30, or 37.04%, closing at $3.91 per share after the FDA identified deficiencies in its NDA, reflecting market concerns over the company's compliance and future outlook.
- False Statement Allegations: The complaint alleges that Aquestive and its executives violated federal securities laws by failing to disclose the true state of its NDA for Anaphylm, particularly concealing human factors, which could lead to significant investor losses.
- Investor Rights Protection: Faruq & Faruqi encourages affected investors to contact the firm directly to ensure their legal rights are protected, while also inviting whistleblowers and others with information to participate in the investigation, demonstrating a commitment to safeguarding investor interests.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Aquestive Therapeutics, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply by May 4, 2026, to become Lead Plaintiff, which could significantly impact the company's reputation and shareholder confidence.
- FDA Review Delay: On January 9, 2026, Aquestive received a letter from the FDA identifying deficiencies in its New Drug Application for Anaphylm, preventing labeling discussions and effectively delaying approval indefinitely, which may adversely affect the company's future revenue projections.
- Significant Stock Price Drop: Following the FDA news, Aquestive's stock price fell by $2.30, or 37.04%, closing at $3.91 per share, reflecting a pessimistic market sentiment regarding the company's outlook and potentially leading to further erosion of investor confidence.
- Legal Background: Pomerantz LLP is a prominent law firm specializing in securities class action litigation, founded over 85 years ago to advocate for victims of securities fraud and corporate misconduct, and this lawsuit may provide compensation opportunities for affected investors, highlighting the importance of legal frameworks in maintaining market integrity.
See More
Reminder of Class Action Lawsuit for Aquestive Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, allowing investors to pursue compensation without financial burden.
- Case Background: The lawsuit alleges that the defendants failed to disclose critical human factors related to the use of Aquestive's New Drug Application (NDA) for its sublingual film, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's transparency and compliance.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
Faruqi & Faruqi Encourages Investors to Contact Regarding Aquestive Losses
- Legal Investigation: Faruq & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. for securities purchased between June 16, 2025, and January 8, 2026, highlighting concerns for investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 and 212-983-9330 (Ext. 1310) to discuss legal options, demonstrating a commitment to client service.
- Class Action Deadline: Investors should note that May 4, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action against the company, making this date critical for potential claimants.
- Company Background: Aquestive Therapeutics, Inc. (NASDAQ:AQST) focuses on drug delivery technologies and is currently facing legal challenges that may impact investor confidence and market performance.
See More
Rosen Law Firm Alerts Investors of Class Action for Aquestive Therapeutics
- Class Action Notification: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ:AQST) securities between June 16, 2025, and January 8, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which mitigates financial risk for investors and encourages broader participation.
- Case Background: The lawsuit alleges that the defendants failed to disclose the true state of Aquestive's New Drug Application (NDA), particularly concealing human factors related to the use of its sublingual film, resulting in investor losses when the truth emerged, highlighting significant governance and transparency issues within the company.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and influence in this field.
See More
Reminder of Class Action for Aquestive Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aquestive Therapeutics (NASDAQ: AQST) securities between June 16, 2025, and January 8, 2026, to apply as lead plaintiffs by May 4, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, allowing them to seek legal recourse without financial burden.
- Case Background: The lawsuit alleges that the defendants made false or misleading statements regarding the New Drug Application (NDA) process, failing to disclose critical human factors involved in the use of their sublingual film, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first by ISS Securities Class Action Services in 2017, highlighting its expertise and success in this field.
See More
Faruqi & Faruqi Investigates Securities Fraud Claims Against Aquestive
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Aquestive Therapeutics, Inc. for actions between June 16, 2025, and January 8, 2026, urging investors to seek lead plaintiff status in a class action by the May 4, 2026 deadline.
- Stock Price Plunge: On January 9, 2026, Aquestive's stock fell by $2.30, or 37.04%, closing at $3.91 per share after the FDA identified deficiencies in its NDA, reflecting market concerns over the company's compliance and future outlook.
- False Statement Allegations: The complaint alleges that Aquestive and its executives violated federal securities laws by failing to disclose the true state of its NDA for Anaphylm, particularly concealing human factors, which could lead to significant investor losses.
- Investor Rights Protection: Faruq & Faruqi encourages affected investors to contact the firm directly to ensure their legal rights are protected, while also inviting whistleblowers and others with information to participate in the investigation, demonstrating a commitment to safeguarding investor interests.
See More
Class Action Lawsuit Filed Against Aquestive Therapeutics
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Aquestive Therapeutics, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply by May 4, 2026, to become Lead Plaintiff, which could significantly impact the company's reputation and shareholder confidence.
- FDA Review Delay: On January 9, 2026, Aquestive received a letter from the FDA identifying deficiencies in its New Drug Application for Anaphylm, preventing labeling discussions and effectively delaying approval indefinitely, which may adversely affect the company's future revenue projections.
- Significant Stock Price Drop: Following the FDA news, Aquestive's stock price fell by $2.30, or 37.04%, closing at $3.91 per share, reflecting a pessimistic market sentiment regarding the company's outlook and potentially leading to further erosion of investor confidence.
- Legal Background: Pomerantz LLP is a prominent law firm specializing in securities class action litigation, founded over 85 years ago to advocate for victims of securities fraud and corporate misconduct, and this lawsuit may provide compensation opportunities for affected investors, highlighting the importance of legal frameworks in maintaining market integrity.
See More
